Apogee Therapeutics’ (APGE) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE) in a research report report published on Monday morning,RTT News reports. They currently have a $90.00 target price on the stock.

A number of other brokerages also recently issued reports on APGE. Guggenheim reissued a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Finally, Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $88.83.

Apogee Therapeutics Trading Up 3.5 %

Shares of NASDAQ:APGE opened at $31.43 on Monday. Apogee Therapeutics has a 12-month low of $29.10 and a 12-month high of $72.29. The company has a market capitalization of $1.42 billion, a PE ratio of -12.99 and a beta of 2.46. The business has a 50 day moving average of $39.67 and a two-hundred day moving average of $47.21.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). Equities research analysts predict that Apogee Therapeutics will post -3.09 earnings per share for the current fiscal year.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 3,520 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total transaction of $143,228.80. Following the completion of the sale, the insider now directly owns 252,623 shares in the company, valued at approximately $10,279,229.87. The trade was a 1.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Thomas Henderson sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $40.58, for a total value of $608,700.00. Following the sale, the chief executive officer now owns 1,302,987 shares of the company’s stock, valued at $52,875,212.46. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,145 shares of company stock valued at $1,897,799 in the last three months. 36.10% of the stock is currently owned by company insiders.

Institutional Trading of Apogee Therapeutics

Several large investors have recently made changes to their positions in APGE. GF Fund Management CO. LTD. purchased a new stake in Apogee Therapeutics in the 4th quarter valued at $43,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Apogee Therapeutics in the 3rd quarter valued at $71,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Apogee Therapeutics by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock valued at $94,000 after buying an additional 285 shares in the last quarter. Wexford Capital LP purchased a new stake in Apogee Therapeutics in the 3rd quarter valued at $230,000. Finally, Optimize Financial Inc purchased a new stake in Apogee Therapeutics in the 4th quarter valued at $203,000. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.